Noteworthy Price Action: pSivida Corp. Just Recorded A Sigfniciant Increase

Noteworthy Price Action: pSivida Corp. Just Recorded A Sigfniciant Increase

The stock of pSivida Corp. (NASDAQ:PSDV) is a huge mover today! About 129,100 shares traded hands. pSivida Corp. (NASDAQ:PSDV) has declined 35.47% since April 4, 2016 and is downtrending. It has underperformed by 36.56% the S&P500.
The move comes after 8 months positive chart setup for the $66.94M company. It was reported on Nov, 4 by Barchart.com. We have $3.58 PT which if reached, will make NASDAQ:PSDV worth $52.21 million more.

According to Zacks Investment Research, “pSivida Corp., a specialty pharmaceutical company, combines existing drugs with its sustained release delivery technologies to develop transformational products primarily in ophthalmology. pSivida’s two proprietary technology systems are Durasert and Tethadur. Durasert delivers specific quantities of drugs at controlled rates for predetermined periods of time from weeks to months. pSivida has developed three of the four sustained delivery release devices for retinal diseases that have been approved in either the US or Europe, the most recent being ILUVIEN®, partnered with Alimera Sciences and approved in multiple EU countries. Independently, pSivida is developing an injectable, bioerodible product to treat glaucoma and ocular hypertension. Tethadur is a protein, peptide and antibody delivery system.”

Insitutional Activity: The institutional sentiment decreased to 0.73 in 2016 Q2. Its down 0.08, from 0.81 in 2016Q1. The ratio worsened, as 6 funds sold all pSivida Corp. shares owned while 9 reduced positions. 4 funds bought stakes while 7 increased positions. They now own 10.25 million shares or 3.57% less from 10.63 million shares in 2016Q1.
Fisher Asset Mngmt Llc holds 0% or 12,057 shares in its portfolio. Springbok Capital Management Limited Company last reported 0% of its portfolio in the stock. Susquehanna Interest Group Ltd Liability Partnership holds 10,139 shares or 0% of its portfolio. Bard Assocs owns 105,609 shares or 0.16% of their US portfolio. Deutsche Comml Bank Ag last reported 0% of its portfolio in the stock. Private Advisor Gp Limited Com holds 0% of its portfolio in pSivida Corp. (NASDAQ:PSDV) for 22,700 shares. Bridgeway Cap last reported 0.01% of its portfolio in the stock. Acadian Asset Mgmt Lc holds 0% or 41,798 shares in its portfolio. North Run Capital Limited Partnership has invested 0.91% of its portfolio in pSivida Corp. (NASDAQ:PSDV). Credit Suisse Ag holds 52,440 shares or 0% of its portfolio. Matrix Asset Advisors Incorporated Ny has 0.02% invested in the company for 30,500 shares. Moreover, National Bank & Trust Of New York Mellon Corp has 0% invested in pSivida Corp. (NASDAQ:PSDV) for 57,637 shares. Morgan Stanley reported 274,233 shares or 0% of all its holdings. Northern Trust last reported 0% of its portfolio in the stock. Wells Fargo Mn holds 1,000 shares or 0% of its portfolio.

More important recent pSivida Corp. (NASDAQ:PSDV) news were published by: Globenewswire.com which released: “Topline Results from First Phase 3 Trial of pSivida’s Medidurâ„¢ Presented at …” on August 15, 2016, also Quotes.Wsj.com published article titled: “News pSivida Corp.PSDV”, Globenewswire.com published: “pSivida Corp. Strengthens Board of Directors With Leading Ophthalmologist” on September 27, 2016. More interesting news about pSivida Corp. (NASDAQ:PSDV) was released by: Seekingalpha.com and their article: “PSivida: ~$4 Ocular Concern Is ‘Looking Good'” with publication date: September 10, 2016.

PSDV Company Profile

pSivida Corp., incorporated on March 20, 2008, develops drug delivery products primarily for the treatment of chronic eye diseases. The Firm operates through the biotechnology sector segment. The Firm has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert. The Company’s product development program is focused primarily on utilizing its two core technology platforms, Durasert and Tethadur, to deliver drugs and biologics to treat chronic diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment